evaluation of [18f] pbr06 and pet as a marker of inflammation in subjects with neurological conditions

Conditions: Alzheimer Disease; Parkinson Disease; Multiple Sclerosis

Summary: the underlying goal of this study is to assess \[18f\] pbr06 pet imaging as a tool to detect microglial activation in the brain of alzheimer disease (ad), parkinson disease (pd) and multiple sclerosis (ms) research participants.


Eligibility criteria:
inclusion criteria: * the following criteria will be met for inclusion of ad subjects in this study: * the participant is 50 years or older. * written informed consent is obtained. * participants have a clinical diagnosis of probable alzheimer's disease based on national institute of neurological and communicative disorders and stroke/alzheimer's disease and related disorders association (nincds/adrda) criteria. * clinical dementia rating scale score ≤ 2. * modified hachinski ischemia scale score of ≤ 4. * for females, non-child bearing potential or a negative urine or blood pregnancy test on day of \[18f\]-pbr06 injection. * the following criteria will be met for inclusion of pd subjects in this study: * the participant is 30 years or older. * written informed consent is obtained. * participants have a clinical diagnosis of parkinson disease (at least two of the three cardinal symptoms: resting tremor, rigidity, bradykinesia). * hoehn and yahr ≤4. * for females, non-child bearing potential or a negative urine or blood pregnancy test on day of \[18f\]-pbr06 injection. * the following criteria will be met for inclusion of ms subjects in this study: * the participant is 18 years or older. * written informed consent is obtained. * participants have a clinical diagnosis of multiple sclerosis (per the 2005 revised mcdonald criteria; polman, et al., 2005). * kurtzke expanded disability status scale (edss) ≤ 7.5. * for females, non-child bearing potential or a negative urine or blood pregnancy test on day of \[18f\]-pbr06 injection * the following criteria will be met for inclusion of healthy control subjects in this study: * the participant is 18 years or older. * written informed consent is obtained. * negative history of neurological or psychiatric illness based on evaluation by a research physician. * clinical dementia rating score = 0. * for females, non-child bearing potential a negative urine or blood pregnancy test on day of \[18f\]-pbr06 injection. exclusion criteria: * alzheimer's subjects will be excluded from participation for the following reasons: * the subject has a history of significant cerebrovascular disease. * the subject has a clinically significant abnormal laboratory value and/or clinically significant unstable medical or psychiatric illness * the subject has evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or other disorder or disease. * pregnancy * parkinson's subjects will be excluded from participation for the following reasons: * the subject has a clinically significant abnormal laboratory value and/or clinically significant unstable medical or psychiatric illness * the subject has evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or other disorder or disease. * pregnancy * ms subjects will be excluded from participation for the following reasons: * the subject has a clinically significant abnormal laboratory value and/or clinically significant unstable medical or psychiatric illness * the subject has evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or other disorder or disease. * pregnancy * healthy control subjects will be excluded from participation for the following reasons: * the subject has a clinically significant abnormal laboratory value and/or clinically significant unstable medical or psychiatric illness. * the subject has evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or other disorder or disease. * pregnancy